指南与共识神经MR

组织病理学验证的多发性硬化皮质病灶成像建议

Histopathology-validated recommendations for cortical lesion imaging in multiple sclerosis.
指南 / 共识 · Brain · 2020-01-01

该回顾性研究对23例进展型多发性硬化患者尸检后未固定冠状半球脑切片行3T MRI,比较T1、质子密度/T2、FLAIR、双反转恢复和相位敏感反转恢复序列对组织病理学验证的皮质病灶的敏感度和特异度。组织病理学检出224个皮质病灶,多数为软膜下病灶;双反转恢复和相位敏感反转恢复敏感度分别为22.8%和23.7%,特异度分别为91.1%和88.3%,两者敏感度和特异度无显著差异。结论认为在3T下双反转恢复和相位敏感反转恢复优于常规序列,推荐用于多发性硬化皮质病灶评估。

要点

  • 双反转恢复和相位敏感反转恢复序列在3T下对皮质病灶的敏感度分别为22.8%和23.7%,特异度分别为91.1%和88.3%。
  • 双反转恢复与相位敏感反转恢复的敏感度和特异度无显著差异,但回顾性分析中相位敏感反转恢复检出更多病灶(126 vs 95,P < 0.001)。
  • 推荐使用双反转恢复和相位敏感反转恢复序列用于多发性硬化皮质病灶的优化评估。

诊断标准与关键数值

  • T1序列敏感度8.9%(20个皮质病灶),特异度80.0%。
  • 质子密度/T2序列敏感度5.4%(12个皮质病灶),特异度75.0%。
  • FLAIR序列敏感度5.4%(12个皮质病灶),特异度80.0%。
  • 双反转恢复序列敏感度22.8%(51个皮质病灶),特异度91.1%。
  • 相位敏感反转恢复序列敏感度23.7%(53个皮质病灶),特异度88.3%。

临床应用与阅片要点

  • 作者推荐使用双反转恢复和相位敏感反转恢复序列用于多发性硬化皮质病灶的优化评估。
  • 双反转恢复和相位敏感反转恢复序列在3T下敏感度不超过25%,但使用现有评分标准时病理特异度高。
  • 双反转恢复与相位敏感反转恢复敏感度和特异度无显著差异,回顾性分析中相位敏感反转恢复检出更多病灶(126 vs 95,P < 0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Cortical demyelinating lesions are clinically important in multiple sclerosis, but notoriously difficult to visualize with MRI. At clinical field strengths, double inversion recovery MRI is most sensitive, but still only detects 18% of all histopathologically validated cortical lesions. More recently, phase-sensitive inversion recovery was suggested to have a higher sensitivity than double inversion recovery, although this claim was not histopathologically validated. Therefore, this retrospective study aimed to provide clarity on this matter by identifying which MRI sequence best detects histopathologically-validated cortical lesions at clinical field strength, by comparing sensitivity and specificity of the thus far most commonly used MRI sequences, which are T2, fluid-attenuated inversion recovery (FLAIR), double inversion recovery and phase-sensitive inversion recovery. Post-mortem MRI was performed on non-fixed coronal hemispheric brain slices of 23 patients with progressive multiple sclerosis directly after autopsy, at 3 T, using T1 and proton-density/T2-weighted, as well as FLAIR, double inversion recovery and phase-sensitive inversion recovery sequences. A total of 93 cortical tissue blocks were sampled from these slices. Blinded to histopathology, all MRI sequences were consensus scored for cortical lesions. Subsequently, tissue samples were stained for proteolipid protein (myelin) and scored for cortical lesion types I-IV (mixed grey matter/white matter, intracortical, subpial and cortex-spanning lesions, respectively). MRI scores were compared to histopathological scores to calculate sensitivity and specificity per sequence. Next, a retrospective (unblinded) scoring was performed to explore maximum scoring potential per sequence. Histopathologically, 224 cortical lesions were detected, of which the majority were subpial. In a mixed model, sensitivity of T1, proton-density/T2, FLAIR, double inversion recovery and phase-sensitive inversion recovery was 8.9%, 5.4%, 5.4%, 22.8% and 23.7%, respectively (20, 12, 12, 51 and 53 cortical lesions). Specificity of the prospective scoring was 80.0%, 75.0%, 80.0%, 91.1% and 88.3%. Sensitivity and specificity did not significantly differ between double inversion recovery and phase-sensitive inversion recovery, while phase-sensitive inversion recovery identified more lesions than double inversion recovery upon retrospective analysis (126 versus 95; P < 0.001). We conclude that, at 3 T, double inversion recovery and phase-sensitive inversion recovery sequences outperform conventional sequences T1, proton-density/T2 and FLAIR. While their overall sensitivity does not exceed 25%, double inversion recovery and phase-sensitive inversion recovery are highly pathologically specific when using existing scoring criteria and their use is recommended for optimal cortical lesion assessment in multiple sclerosis.

来源:Brain,查看原文。版权归原作者所有。

引用

  1. Bouman PM, Steenwijk MD, Pouwels PJW, et al. Histopathology-validated recommendations for cortical lesion imaging in multiple sclerosis. Brain. 2020. PMID: 32889535. doi:10.1093/brain/awaa233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。